CareDx Issues Statement On Supreme Court Decision Regarding Stanford-Licensed Patents; Says Decision Has No Impact On Its Ability to Continue Providing AlloSure dd-cfDNA
Portfolio Pulse from Benzinga Newsdesk
CareDx has issued a statement regarding a Supreme Court decision on Stanford-licensed patents, stating that the decision will not impact its ability to continue providing AlloSure dd-cfDNA.
October 03, 2023 | 10:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The Supreme Court decision on Stanford-licensed patents does not impact CareDx's ability to provide AlloSure dd-cfDNA.
The Supreme Court decision, while related to patents licensed by Stanford, does not directly impact CareDx's operations or its ability to provide AlloSure dd-cfDNA. This suggests that the company's operations and stock price should remain stable in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
The news does not mention Natera (NTRA) directly and therefore it is not expected to have any impact on the company.
The news does not mention Natera (NTRA) directly and therefore it is not expected to have any impact on the company.
CONFIDENCE 100
IMPORTANCE 0
RELEVANCE 0